Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015522 | 0.89 | RAB9A (0.55) | RAB9ANPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL1013563 | 0.86 | KMT2A (0.53) | RAB9ANPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL1013555 | 0.84 | KMT2A (0.48) | RAB9ANPC1ALDH1A1KDM4ERXFP1 | |
| SCHEMBL1013722 | 0.83 | SERPINE1 (0.52) | NPC1ALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL1015370 | 0.81 | KDM4E (0.60) | ALDH1A1KDM4ELMNARXFP1SMN1; SMN2 | |
| SCHEMBL1014502 | 0.81 | SERPINE1 (0.52) | ALDH1A1KDM4ESMN1; SMN2HPGDKMT2A | |
| SCHEMBL1797516 | 0.80 | ALDH1A1 (0.50) | ALDH1A1KDM4ELMNARXFP1SMN1; SMN2 | |
| SCHEMBL7125633 | 0.80 | ALDH1A1 (0.62) | ALDH1A1KDM4ELMNARXFP1SMN1; SMN2 | |
| SCHEMBL1014777 | 0.80 | ALDH1A1 (0.46) | RAB9ANPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL495339 | 0.79 | YAP1 (0.65) | RAB9ANPC1ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415479-B2 | Inhibitor of plasminogen activator inhibitor-1 | RENASCIENCE CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | RENASCIENCE CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2272822-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | Renascience CO., LTD. (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | SERPINE1, SERPINB1, SERPINC1 | RAB9A 2950/4885NPC1 1613/4885ALDH1A1 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.